Your browser doesn't support javascript.
Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management.
Heskin, Joseph; Pallett, Scott J C; Mughal, Nabeela; Davies, Gary W; Moore, Luke S P; Rayment, Michael; Jones, Rachael.
  • Heskin J; Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK. Electronic address: j.heskin@nhs.net.
  • Pallett SJC; Royal Defence Medical College, Royal Centre for Defence Medicine, Birmingham, UK.
  • Mughal N; Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK.
  • Davies GW; Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK.
  • Moore LSP; Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK.
  • Rayment M; Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK.
  • Jones R; Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK.
Lancet ; 399(10319): 21-22, 2022 01 01.
Article in English | MEDLINE | ID: covidwho-1586219
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Proline / Ritonavir / Viral Protease Inhibitors / COVID-19 Drug Treatment / Lactams / Leucine / Nitriles Limits: Humans Language: English Journal: Lancet Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Proline / Ritonavir / Viral Protease Inhibitors / COVID-19 Drug Treatment / Lactams / Leucine / Nitriles Limits: Humans Language: English Journal: Lancet Year: 2022 Document Type: Article